The content on this site is intended for healthcare professionals only
Highlights in melanoma from ASCO 2024
ASCO 2024: Highlights and analysis
Melanoma outcomes improved by dual immunotherapy before surgery rather than after
Neoadjuvant daromun effective and safe for resectable, locally advanced melanoma
2 year recurrence free survival benefit for resectable melanoma treated with neoadjuvant/adjuvant pembrolizumab
Neoadjuvant cemiplimab shows favourable event-free, disease-free and overall survival rates in patients with resectable CSCC
Myeloma treatment and prognosis
Interpreting the results of a clinical trial
Breast cancer screening global approaches
How to approach a breast lump and nipple discharge
Axillary management
Looking at radioiodine and other radio-labelled metabolites for thyroid cancers
